After finishing at $15.68 in the prior trading day, Hims & Hers Health Inc (NYSE: HIMS) closed at $15.64, down -0.26%. In other words, the price has decreased by -$0.04 from its previous closing price. On the day, 4259362 shares were traded.
Ratios:
Our goal is to gain a better understanding of HIMS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 68.50. For the most recent quarter (mrq), Quick Ratio is recorded 2.74 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $10.
On December 07, 2023, Imperial Capital started tracking the stock assigning a In-line rating and target price of $9.Imperial Capital initiated its In-line rating on December 07, 2023, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 19 ’24 when Becklund Irene sold 13,353 shares for $15.52 per share. The transaction valued at 207,239 led to the insider holds 0 shares of the business.
O’Keefe Lynne Chou sold 10,044 shares of HIMS for $155,883 on Mar 19 ’24. The Director now owns 0 shares after completing the transaction at $15.52 per share. On Mar 18 ’24, another insider, Becklund Irene, who serves as the PAO of the company, sold 472 shares for $14.70 each. As a result, the insider received 6,938 and left with 13,353 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 3.36B and an Enterprise Value of 3.15B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.84 while its Price-to-Book (P/B) ratio in mrq is 9.71. Its current Enterprise Value per Revenue stands at 3.61 whereas that against EBITDA is -157.91.
Stock Price History:
Over the past 52 weeks, HIMS has reached a high of $15.77, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 10.79, while the 200-Day Moving Average is calculated to be 8.42.
Shares Statistics:
The stock has traded on average 4.38M shares per day over the past 3-months and 5.64M shares per day over the last 10 days, according to various share statistics. A total of 205.10M shares are outstanding, with a floating share count of 138.88M. Insiders hold about 35.18% of the company’s shares, while institutions hold 38.57% stake in the company. Shares short for HIMS as of Feb 29, 2024 were 12.65M with a Short Ratio of 2.89, compared to 14.42M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.90% and a Short% of Float of 7.92%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.04, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.14 and -$0.11 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is $0.2, with 9 analysts recommending between $0.33 and $0.02.
Revenue Estimates
9 analysts predict $270.5M in revenue for the current quarter. It ranges from a high estimate of $271.65M to a low estimate of $268.9M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $190.77M, an estimated increase of 41.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $288.5M, an increase of 40.80% less than the figure of $41.80% in the same quarter last year. There is a high estimate of $291.91M for the next quarter, whereas the lowest estimate is $286.5M.
A total of 11 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $1.2B, while the lowest revenue estimate was $1.18B, resulting in an average revenue estimate of $1.19B. In the same quarter a year ago, actual revenue was $878M, up 35.70% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $1.48B in the next fiscal year. The high estimate is $1.56B and the low estimate is $1.42B. The average revenue growth estimate for next year is up 24.40% from the average revenue estimate for this year.
